Belite Bio (BLTE) Operating Expenses (2022 - 2026)

Belite Bio's Operating Expenses history runs 5 years deep, the most recent figure standing at $32.7 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 110.63% year-over-year to $32.7 million; the TTM figure through Mar 2026 stood at $68.7 billion (up 116.91% YoY), while the FY2025 annual figure was $84.2 million, up 110.54% from the prior year.
• Operating Expenses for Q1 2026 stood at $32.7 million, down from $28.1 billion in the prior quarter.
• The five-year high for Operating Expenses was $28.1 billion in Q4 2025, with the low at $6.7 million in Q4 2022.
• The 5-year median for Operating Expenses is $6.9 billion (2023), against an average of $8.0 billion.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses surged 164630.41% in 2024, then plunged 99.81% in 2025.
• Belite Bio's Operating Expenses stood at $6.7 million in 2022, then grew by 3.48% to $7.0 million in 2023, then soared by 164630.41% to $11.5 billion in 2024, then soared by 145.06% to $28.1 billion in 2025, then plunged by 99.88% to $32.7 million in 2026.
• Business Quant data shows BLTE's Operating Expenses at $32.7 million in Q1 2026, $28.1 billion in Q4 2025, and $23.0 billion in Q3 2025.